CRISPR-edited immune cells combat advanced colorectal cancer

A first-in-human clinical trial using CRISPR gene editing to treat advanced colorectal cancer shows promising results, including a complete response in one patient. The treatment uses modified immune cells to target and attack cancer cells. Researchers used CRISPR/Cas9 to modify tumor-infiltrating lymphocytes (TILs), deactivating the CISH gene to enhance their ability to fight cancer. The trial, involving 12 patients, found the treatment generally safe, with some patients showing halted cancer growth. The study, published in The Lancet Oncology, highlights the potential of this approach for late-stage disease. While the process is complex, researchers are working to streamline production and understand the therapy's effectiveness.